Reply to “GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?”

We appreciated Du et al.'s valuable comments on our recent study. [1] As described by the author, the reduced trend of a composite ischemic outcome in the glucagon-like peptide-1 receptor agonists (GLP1RA) group, compared to the sodium-glucose cotransporter 2 inhibitors (SGLT2i) group, was mainly derived by acute coronary syndrome (ACS). However, despite the lack of statistical significance due to the low event rates, it was noted that the annualized rates (per 100 person-year) for each component of ischemic events were lower in the GLP1RA group than SGLT2i group: ACS 0.25 vs.

Source: International Journal of Cardiology - August 23, 2022 Category: Cardiology Authors: In-Chang Hwang, Chee Hae Kim Tags: Letter to the Editor Source Type: research